[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer-blood-biomarkers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer-blood-biomarkers":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,93,120,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645292","the-bridge-towards-implementation-of-blood-based-biomarkers-to-enable-early-and-accurate-diagnosis-of-alzheimers-disease-100645292",false,"NCT07680335","The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease","The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease (BRIDGE-AD2)","BRIDGE-AD2","Inclusion Criteria:\n\n* Patient presents in memory clinic with cognitive complaints.\n* The physician is concerned about underlying AD as etiology of the complaints.\n* Adequate fluency in Dutch to understand informed consent procedure.\n\nExclusion Criteria:\n\n* Age under 55.\n* Previous biomarker-confirmed diagnosis of AD.\n* Alcohol or drug abuse to such an extent that treatment would be advisable.\n* Patient is incapacitated, and is not able to judge consequences of participation.","ALL","55 Years",{"count":20,"type":21},550,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cognitive disorders have a broad differential diagnosis, and a precise, timely diagnosis is essential for personalized treatment and care. Currently, dementia diagnoses are often not further specified according to the underlying pathology and are frequently delayed by several years. However, with the upcoming disease-modifying treatments (DMTs) for AD, an accurate, pathology-driven (i.e., etiological) diagnosis will become necessary.\n\nBlood-based biomarkers (BBMs) are promising tools for detecting Alzheimer's disease (AD), with current research showing high concordance with cerebrospinal fluid (CSF) biomarkers and amyloid PET imaging. However, it remains unclear how physicians would value the availability of BBMs for AD in routine clinical practice. The investigators hypothesize that BBMs will benefit both patients and physicians in the diagnostic process within a memory clinic setting.\n\nThis study aims to investigate clinical impact and diagnostic utility of blood-based biomarkers for AD in the diagnostic process of a memory clinic. The main objectives are to investigate change in diagnosis, diagnostic certainty and patient management, due to BBM results.",[27,28],"Alzheimer Blood Biomarkers","Alzheimer's Disease (AD)",[30],"Randomised diagnostic trial","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2025-09-17",{"date":39,"type":21},"2027-06-30",{"name":41,"class":42},"Alzheimercentrum Amsterdam","OTHER",8,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":68,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":5},"100610985","phase-3-levetiracetam-to-prevent-seizures-in-symptomatic-alzheimers-disease-in-adults-with-down-syndrome-100610985","NCT07234695","LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome","A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).","LESS-AD","Inclusion Criteria:\n\n* Diagnosed with Down Syndrome (DS), either with a karyotype or a compatible typical phenotype.\n* Age over 40 years at time of screening.\n* Symptomatic Alzheimer's Disease (AD) dementia, based on change in functionality and neuropsychological tests' results. Different cut-off points will be established to diagnose dementia depending on the level of intellectual disability of the individual, according to previous experience (Benejam et al; 2020): in adults with mild intellectual disability, a CAMCOG-DS score of 80 and an mCRT score of 29 will be chosen, whereas values of 56 and 28, respectively, will be used in subjects with moderate intellectual disability. Doubtful cases (e.g., with compromised functionality, but without alteration in the neuropsychological assessment) or those unable to complete the evaluation will be categorized by consensus among expert clinicians, using all available clinical information.\n* Willing and able caregiver who has daily contact with the study subject.\n* Subjects and caregivers must be able to comply with the prescribed regimen of study treatment throughout the course of the study and meet a minimum required time commitment of biannual in-person visits.\n* Any concurrent treatment for AD approved by the European Medicines Agency (EMA) must be stable for at least 30 days prior to screening and at least 60 days prior to study day 1. Other medications (except for those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to screening.\n* Subjects and\u002For their caregivers must be able to provide their consent before participating in any study-related procedures.\n\nExclusion Criteria:\n\n* Cognitive changes attributable to causes other than AD (for example, but not limited to, uncorrected visual or hearing deficit, severe, untreated sleep apnea or uncontrolled thyroid disorders).\n* Previous history of adult-onset epileptic seizures (over 18 years old).\n* Treatment with any kind of antiepileptic drugs, benzodiazepines, narcotics.\n* Significant comorbidities or analytical abnormalities, such as:\n* Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of the study (eg, moderate and\u002For severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator's judgement.\n* Severe renal dysfunction (creatinine clearance \\\u003C 30 mL\u002Fmin), which would affect serum levetiracetam levels, or any other medical condition which is determined by the investigators to potentially create an undue risk for an adverse effect.\n* Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson's disease, severe carotid occlusive disease, transient ischemic attacks \\[TIAs\\]).\n* Significant risk of suicide, defined using the C-SSRS as the subject answering \"yes\" to suicidal ideation questions 4 or 5 or answering \"yes\" to suicidal behavior within the past 12 months.\n* Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.\n* Participation in another clinical trial within 3 months of screening.\n* Hypersensitivity to the active ingredient, other pyrrolidone derivatives, or any of the excipients\n* Pregnant and breastfeeding patients","40 Years",{"count":54,"type":21},120,[56],"PHASE3","The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease.\n\nPatients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo.\n\nBoth groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.",[59,60,61,62,63,64,65,27,66,67],"Down Syndrome","Down Syndrome (DS)","Down Syndrome (Trisomy 21)","Alzheimer Dementia","Alzheimer Dementia (AD)","Alzheimer Disease","Alzheimer Disease (AD)","Epilepsy","Seizures",[69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Down syndrome","epilepsy","Alzheimer","dementia","levetiracetam","prevention","placebo-controlled","epileptic seizures","Alzheimer's disease markers","phase III","randomized","double-blind","bilateral tonic-clonic seizure","217-pTau","NfL","2026-01-08",{"date":86,"type":35},"2026-01-12",{"date":88,"type":21},"2025-12-22",{"date":90,"type":21},"2028-07",{"name":92,"class":42},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100613341","effect-of-physiologic-insulin-administration-on-insulin-sensitivity-and-cognition-100613341","NCT07265323","Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition","Effect of Physiologic Insulin Intervention on Insulin Sensitivity and Cognition","MIND-IT","Inclusion Criteria:\n\n* Mini Mental State Examination (MMSE) score \\\u003C 25\n\nExclusion Criteria:\n\n* On daily medication for the specific treatment of anxiety including benzodiazepines.\n* An infant, child, or teenager\n* A pregnant woman\n* A prisoner\n* Having any condition that impedes testing of the study hypothesis or are otherwise deemed to be unsuitable (determined by the investigative team).","18 Years",{"count":43,"type":21},[24],"The goal of this clinical trial is to determine if a weekly delivery of insulin at short intervals lasting up to 2 hours can improve insulin sensitivity and cognition in adults with Alzheimer's Disease. It will also provide information about the safety and feasibility of this intervention.\n\nThe main questions it aims to answer are:\n\nDoes the intervention improve insulin sensitivity (how the body uses glucose)?\n\nDoes the intervention improve cognition, measured by the Montreal Cognitive Assessment (MoCA) and the Revised Memory and Behavior Problems Checklist (RMBPC)?\n\nWhat changes occur in brain glucose uptake (FDG-PET)?\n\nParticipants will:\n\nReceive the intervention once a week for 6 months, with each session lasting up to 2 hours\n\nComplete cognitive assessments. Adverse events will be assessed throughout the study.",[106,27,107],"Alzheimer s Disease","Insulin Sensitivity",[109,107],"Alzheimer's disease","2025-12-02",{"date":112,"type":35},"2025-12-04",{"date":114,"type":21},"2025-12",{"date":116,"type":21},"2027-05",{"name":118,"class":42},"Pennington Biomedical Research Center",1,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":17,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":119},"100604199","impact-of-a-multimodal-lifestyle-intervention-on-dementia-risk-factors-and-attitude-related-to-dementia-risk-a-logistical-pilot-study-100604199","NCT07146412","Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study","Inclusion Criteria:\n\n* Adults 65-75 years of age at enrollment with at least one self-reported 1st-degree relative who had or has any kind of dementia\n* Montreal Cognitive Assessment (MoCA) score \\> 24 at initial enrollment\n* Able and willing to comprehend and sign the informed consent document\n* Able and willing to perform required physical performance tests\n* Able and willing to provide the study's minimum samples\n* Able and willing to conduct the study's minimum procedures\n* Able and willing to complete surveys, cognitive assessments, and questionnaires in English only\n* Has or has ready access to a PC, tablet, or smartphone with an internet connection required for procedures that they consent to\n\nExclusion Criteria:\n\n* A diagnosis of cognitive impairment of any kind, including Alzheimer's disease, mild cognitive impairment, or any other diagnosis of dementia\n* If a subject is found to have cognitive impairment at initial enrollment (Montreal Cognitive Assessment (MoCA) score\\\u003C25), they will be excluded from the study\n* Self-reported pregnancy\n* Children under 19 years of age\n* Individuals not fluent in written and spoken English\n* Self-reported chronic or end-stage disease that would interfere with their participation in the study\n* Hospitalization for any reason in the past 3 months\n* Severe hearing and visual impairment that would interfere with the ability to complete study measures\n* Any other vulnerable subject at the time of enrollment as specified above",true,"65 Years","75 Years",{"count":130,"type":21},200,[24],"Many individuals develop dementia, and dementia has multiple causes, yet we currently have limited treatment options. A critical observation of the effectiveness of the available dementia treatments is that they tend to be more effective when started early. Previous studies have shown that multimodal lifestyle interventions can significantly delay the onset of Alzheimer's dementia in individuals with high risk for Alzheimer's or with Mild Cognitive Impairment (MCI). These interventions may be less effective when initiated after dementia has already been diagnosed or is more advanced.\n\nThis study has two primary goals. The first goal is to assess attitudes around dementia risk for participants throughout the study as they learn of their personalized risk and possible lifestyle factors that may modify that risk. The second goal is to serve as a logistical pilot for the implementation of data collection and processing and multimodal lifestyle intervention to reduce the risk factors of dementia in individuals without current cognitive impairment but who are at high risk of progression to dementia. Secondary goals of this study include better defining what factors contribute the most risk to dementia and identifying sub-types of dementia defined by different genetic and molecular risk factors.",[134,27,65,135],"Cognitive Impairment","Mild Cognitive Impairment (MCI)",[137,138,139,140,141],"alzheimer","cognitive impairment","APOE","PRS","pTau217","2025-08-22",{"date":144,"type":35},"2025-08-28",{"date":146,"type":35},"2025-05-02",{"date":148,"type":21},"2026-04-30",{"name":150,"class":42},"HudsonAlpha Institute for Biotechnology",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":119},"100539460","diagnostic-performance-of-plasma-biomarkers-of-alzheimers-disease-compared-with-csf-markers-100539460","NCT06304129","Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers","Threshold Values and Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers","PLASM-ALZ","Inclusion Criteria:\n\n* Man or woman aged 18 or over\n* Person affiliated to a social security scheme or beneficiary of such a scheme\n* Person who has received full information on the organization of the research and has signed an informed consent form\n* Person whose care requires a lumbar puncture to measure markers of Alzheimer's disease\n\nExclusion Criteria:\n\n* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n* An adult unable to give consent\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons under psychiatric care under articles L. 3212-1 and L. 3213-1.\n* Pregnant, parturient or breast-feeding women\n* Persons staying in a health or social establishment for purposes other than research.",{"count":160,"type":21},189,[24],".The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are:\n\n* to define a threshold value for each of the plasma,\n* to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia,\n* to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes\n* to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A\u002FT\u002FN classification (A-\u002FT+ or A+\u002FT-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.",[27],"NOT_YET_RECRUITING","2024-03-05",{"date":167,"type":35},"2024-03-12",{"date":169,"type":21},"2024-04-02",{"date":171,"type":21},"2026-09-02",{"name":173,"class":42},"Central Hospital, Nancy, France"]